Orthopedic Seed Funding in the City
This article was originally published in Start Up
In May 2005, a leading orthopedics hospital, two health-care focused venture capital firms, a real estate investment trust, and a local economic development group came together to form New York Orthopedic Technologies LLC, in order to fill a gap in seed stage investing in orthopedics. The consortium hopes to address several challenges unique to early stage value creation in medical technology: how to bring particular sets of resources to the entrepreneur or physician with a concept-clinical, financial, operational, and logistical; how to get the technology to the next milestone without creating a model that itself requires care and feeding; and how to create a structure that serves the divergent goals of all the participants.
You may also be interested in...
Assembling a Dream Team of surgeons, including those of The Texas Back Institute, as well as leading medical device companies, IST sought to create an incubator in spine unparalleled in its ability to bring new technology to market. The only thing is, the model didn't work. Now, IST has shifted gears and is pursuing a mega-roll up strategy.
Renowned cardiologist Martin Leon, MD, found himself growing frustrated with the tendency of start-ups to bring physicians into the develeopment program too late, when major but critical changes would be impractical if not outright impossible. So Leon and partner Yuval Binur, of Medica Venture Partners, set out to define a new model for device start-up creation, Accelerated Technologies Inc. The company has launched five new cardiovascular device companies and is about to launch a sixth.
Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.